buildleaf smgt glp 1 Mapping the effectiveness and risks of GLP-1 receptor agonists Counterfeit weight loss products claiming

Oral versions are in development to eliminate injections

If you are like me and find that your medical insurance doesn't cover medical weight loss medications, your only option is to pay out of pocket

The electrolyte imbalances that occur with dehydration are particularly problematic

Change in body weight was calculated, and safety data were also analyzed

What is already known on this topic Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors reduce the risk of cardiovascular and renal events in patients with type 2 diabetes These drug classes are increasingly used in combination when previous therapy with other antihyperglycaemic drugs fails Whether the combined use of these drug classes results in improved cardiovascular and renal outcomes in the real world setting, compared with the use of either drug class alone, remains unclear What this study adds This population based cohort study aimed at emulating a randomised controlled trial The combined use of a GLP-1 receptor agonist and an SGLT-2 inhibitor was associated with a lower risk of cardiovascular and serious renal events, compared with either drug class alone These findings highlight the potential benefit of combining these two effective drug classes in preventing cardiovascular and renal events in the treatment of type 2 diabetes Data availability statement This study is based on data from the Clinical Practice Research Datalink obtained under license from the UK Medicines and Healthcare products Regulatory Agency

[DOI] [PMC free article] [PubMed] [Google Scholar] 112.Gutierrez A.D., Gao Z., Hamidi V., Zhu L., Saint Andre K.B., Riggs K., Ruscheinsky M., Wang H., Yu Y., Miller C., III, et al